ImmunityBio (IBRX) return on equity (ROE)

Return on equity · fiscal 2019
-130.7%

ImmunityBio (IBRX) earned a return on equity of -130.7% in fiscal 2019 (the year ended December 31, 2019). That is 64.8 percentage points lower than the -65.9% of fiscal 2018. Figures as of 17 Nov 2026, 22:32 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2019
-130.7%
Change on fiscal 2018
−64.8 pts
Highest on record
-10.7%fiscal 2014
Lowest on record
-130.7%fiscal 2019
Fiscal years on record
62014–2019

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

ImmunityBio return on equity (ROE), in more detail

Across the 6 fiscal years on record (2014–2019), the highest was -10.7% in fiscal 2014 and the lowest -130.7% in fiscal 2019. The fiscal 2019 figure is no higher than in any of the 5 earlier fiscal years on record, whose median is -44.1%.

History · 6 fiscal years

Return on equity by fiscal year

ImmunityBio return on equity (ROE), year by year

ImmunityBio (IBRX) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2019-130.7% 64.8 pts down
2018-65.9% 21.8 pts down
2017-44.1% 2.9 pts down
2016-41.2% 25.4 pts up
2015-66.5% 55.8 pts down
2014-10.7%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of ImmunityBio and comparable companies
CompanyReturn on equityFiscal year
PACS Group PACS20.2%2025
ImmunityBio IBRX-130.7%2019
ABIVAX ABVX-73.8%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on IBRX

ImmunityBio, figure by figure

ImmunityBio (IBRX) overview: price, valuation and scorecardAll health care companies by market value

ImmunityBio return on equity (ROE): questions and answers

What is ImmunityBio's return on equity?

ImmunityBio (IBRX) earned a return on equity of -130.7% in fiscal 2019 (the year ended December 31, 2019). That is 64.8 percentage points lower than the -65.9% of fiscal 2018.

Is ImmunityBio's return on equity high or low compared with its own history?

The fiscal 2019 figure is no higher than in any of the 5 earlier fiscal years on record, whose median is -44.1%.

What are the highest and lowest return on equity figures on record for ImmunityBio?

Across the 6 fiscal years on record (2014–2019), the highest was -10.7% in fiscal 2014 and the lowest -130.7% in fiscal 2019.

How is ImmunityBio's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “ImmunityBio (IBRX) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/IBRX/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.